Research programme: CX 1000 series - Cylene
Alternative Names: CX 1000 series; CX 1322Latest Information Update: 30 Apr 2007
At a glance
- Originator University of Arizona
- Developer Cylene Pharmaceuticals; University of Arizona
- Class Small molecules
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer